Stay invested in Suven Life Sciences: Avinnash Gorakssakar

Avinnash Gorakssakar, Market Expert told CNBC-TV18, "If the investors can hold on for the next 12-18 months, I think Suven Life Sciences is a company which has monetised several drug molecules and there are several Abbreviated New Drug Applications (ANDAs) which the company has filed and our sense is that in the coming year also, some further monetisation could happen."

"On an operational level, the company has been doing pretty well and our sense is that if such monetisation happens then it is going to impact the company quite significantly. So giving it some time, the investors should hold on," he added.